Kura Oncology (KURA) Competitors $6.13 -0.22 (-3.46%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$6.18 +0.05 (+0.80%) As of 07:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KURA vs. INDV, RXRX, DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, and HRMYShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Its Competitors Indivior Recursion Pharmaceuticals Denali Therapeutics Beam Therapeutics Kiniksa Pharmaceuticals International Belite Bio Centessa Pharmaceuticals Vericel Disc Medicine Harmony Biosciences Kura Oncology (NASDAQ:KURA) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation. Which has better earnings & valuation, KURA or INDV? Indivior has higher revenue and earnings than Kura Oncology. Indivior is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$67.99M7.81-$173.98M-$2.10-2.92Indivior$1.19BN/A$2M-$0.31-49.61 Do analysts recommend KURA or INDV? Kura Oncology presently has a consensus price target of $24.50, indicating a potential upside of 299.67%. Indivior has a consensus price target of $17.00, indicating a potential upside of 10.53%. Given Kura Oncology's higher probable upside, equities analysts clearly believe Kura Oncology is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer KURA or INDV? In the previous week, Kura Oncology had 1 more articles in the media than Indivior. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Indivior. Kura Oncology's average media sentiment score of 1.31 beat Indivior's score of 0.62 indicating that Kura Oncology is being referred to more favorably in the media. Company Overall Sentiment Kura Oncology Positive Indivior Positive Is KURA or INDV more profitable? Kura Oncology has a net margin of 0.00% compared to Indivior's net margin of -4.02%. Kura Oncology's return on equity of -43.62% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -43.62% -29.13% Indivior -4.02%-97.29%15.74% Do insiders & institutionals believe in KURA or INDV? 60.3% of Indivior shares are held by institutional investors. 6.4% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, KURA or INDV? Kura Oncology has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. SummaryKura Oncology beats Indivior on 8 of the 15 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$549.75M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-2.9220.2228.5419.58Price / Sales7.81299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book1.157.568.145.54Net Income-$173.98M-$55.11M$3.24B$257.73M7 Day Performance-0.49%3.81%0.18%-0.08%1 Month Performance-5.55%11.60%5.96%8.09%1 Year Performance-73.61%-2.11%26.24%13.02% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology4.5589 of 5 stars$6.13-3.5%$24.50+299.7%-73.1%$549.75M$67.99M-2.92130INDVIndivior1.7709 of 5 stars$15.62+1.0%$17.00+8.8%+47.9%$2.15B$1.17B-50.391,051RXRXRecursion Pharmaceuticals1.804 of 5 stars$5.28flat$7.00+32.6%-36.3%$2.15B$59.82M-2.98400DNLIDenali Therapeutics4.6077 of 5 stars$14.69+1.2%$33.71+129.5%-39.3%$2.13B$330.53M-5.50430Positive NewsBEAMBeam Therapeutics2.2731 of 5 stars$21.17+0.0%$48.75+130.3%-23.6%$2.13B$63.52M-4.59510KNSAKiniksa Pharmaceuticals International3.506 of 5 stars$28.80+2.5%$39.33+36.6%+30.0%$2.10B$423.24M-115.20220Positive NewsUpcoming EarningsBLTEBelite Bio1.9899 of 5 stars$63.58+0.6%$96.67+52.0%+29.2%$2.02BN/A-46.7510High Trading VolumeCNTACentessa Pharmaceuticals3.1598 of 5 stars$15.13+4.9%$27.89+84.3%+58.1%$2.02B$15M-8.36200High Trading VolumeVCELVericel3.6933 of 5 stars$39.82-0.3%$61.14+53.5%-25.6%$2.00B$238.54M1,327.78300News CoveragePositive NewsIRONDisc Medicine3.2038 of 5 stars$57.74+1.5%$96.70+67.5%+14.3%$2.00BN/A-14.7330Insider TradeHRMYHarmony Biosciences4.8358 of 5 stars$34.71+2.1%$51.33+47.9%+2.4%$1.99B$714.73M13.25200News CoveragePositive News Related Companies and Tools Related Companies INDV Alternatives RXRX Alternatives DNLI Alternatives BEAM Alternatives KNSA Alternatives BLTE Alternatives CNTA Alternatives VCEL Alternatives IRON Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KURA Stock Alerts